About 147 employees are affected, about 95% of its workforce, according to Vor Biopharma Inc.'s latest layoff filing, on May 8, 2025. As of November 14, 2026, Vor Biopharma Inc. has reported this one exit or restructuring plan to the SEC on Form 8-K under Item 2.05. No WARN notice under its name is on file in the states covered here (Form 8-K, May 8, 2025).
10 companies announced layoffs this week, 1 had other signals.
Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.
| UPWORK, INC | announced layoffs | |
| PVH CORP. /DE/ | announced layoffs | |
| Battelle | filed a layoff notice for 15 employees | |
| TidalHealth Primary Care | filed a layoff notice for 5 employees | |
| Phunware, Inc. | announced layoffs |
Is this your company?
Owed money by them or selling to them? See the free Snapshot of Vor Biopharma Inc.
Free to see. No signup.
People from Vor Biopharma Inc. who say they are open to work
Only people who added themselves are listed here. Nobody is named because of a company announcement or a news story, and we have not checked what anyone says about themselves.
Loading the list…
Affected by the Vor Biopharma Inc. layoff? Add yourself to the open-to-work list, free
Your entry
Vor Biopharma Inc. reported 1 exit or restructuring plan on Form 8-K under Item 2.05, 1 of 1 stating how many employees or positions are affected. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
Did Vor Biopharma have layoffs in 2025? What its filings say
Vor Biopharma Inc. (CIK 1817229) reported 1 exit or restructuring plan to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K filed 2025-05-08
Employees affected
On May 5, 2025, the board of directors of Vor Biopharma Inc. (the "Company") approved the wind down of the Company's clinical and manufacturing operations as the Company conducts a process to explore strategic alternatives to maximize shareholder value, which includes a plan to implement a reduction of the Company's workforce by 147 full-time employees, or approximately 95% of the Company's current employee base (the "Wind Down").
Locations
The Company estimates that it will incur approximately $3.5 million in contract termination and other costs related to the discontinuation of its clinical trials, approximately $0.5 million in contract termination and other costs related to the exit from its manufacturing facility, an approximately $4.4 million loss on disposal of fixed assets, and approximately $10.9 million in costs related to the workforce reduction.
Expected charges
The total costs related to the Wind Down are estimated to be approximately $19.3 million.
Timing
The Company expects to complete the workforce reduction by the end of the second quarter of 2025 and to incur a significant majority of the costs related to the Wind Down in the second quarter of 2025.
Also on the record for Vor Biopharma Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 4.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Verve Capital Limited | 6.3% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 9.1% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.7% of the class | 5%+ stakes | Source |
| July 21, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 19.9% of the class | 5%+ stakes | Source |
| July 7, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Verve Capital Limited | 9.3% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 3.2% of the class | 5%+ stakes | Source |
Keep reading
More on Vor Biopharma Inc. and the records around it.
Vor Biopharma Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- 5AM Ventures VI, L.P. also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Aug 2026), ARTIVA BIOTHERAPEUTICS, INC. (Aug 2026)
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Crescent Biopharma, Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
Watch Vor Biopharma Inc.
Get an email when Vor Biopharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Vor Biopharma Inc.?
Want the whole picture on Vor Biopharma Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vor Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vor Biopharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 51 records.
Tools for this story
Each opens in a new tab, filled in for Vor Biopharma Inc.. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.
Who owns Vor Biopharma Inc.? Owners, funding and legal record
Cite this page
https://mentionfox.com/layoffs/vor-biopharma